Skip to main content
Premium Trial:

Request an Annual Quote

Roche Obtains FDA 510(k) Clearance for COVID-19 PCR Test

NEW YORK – Roche announced on Monday that its SARS-CoV-2 Qualitative PCR test has received 510(k) clearance from the US Food and Drug Administration.

The RT-PCR test runs on Roche's high-throughput Cobas 6800 and 8800 systems and is intended to detect SARS-CoV-2 from nasal and nasopharyngeal samples in symptomatic patients. The assay has been available in the US under Emergency Use Authorization since March 2020. 

Roche said in a statement that the test's clearance was based on a comprehensive package that included analytical and clinical studies and noted that the assay is able to detect all SARS-CoV-2 variants. 

The firm is also "actively working with health authorities to pursue FDA-cleared status for the tests in our COVID-19 portfolio," Roche Diagnostics CEO Thomas Schinecker said in a statement. 

According to Roche, the Cobas 6800 and 8800 systems can provide results in three and a half hours. The 6800 system can provide a total of 1,440 results in 24 hours while the 8800 system can provide 4,128 results over that same time period.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.